[Perioperative prevention of thromboembolism with low molecular weight heparin and postoperative bleeding complications].
In three studies the effect and secondary effect of low molecular weight heparin (LMWH) were examined. Study 1: LMWH (Embolex-LM, n = 464) versus standard heparin (Liquemin, n = 452); Study 2: LMWH (Sandoparin, n = 298) versus standard heparin (n = 296). In the 3rd study controls of LMWH were performed in the clinic of visceral surgery, and the clinic of traumatology both. During these three studies all excluded patients who did not receive a thromboembolic prophylaxis were also examined. The first two studies showed no significant differences in the frequency of thromboembolic and bleeding complications. The bleeding complication was the same (3-6%) in the group of excluded patients. This is valid for study 3 too. In all studies the surgeon had an important influence on the frequency of bleeding complications.
Hoffman
R
R
Dep. Chirurgie, Universitätsspital, Zürich.
Largiadèr
F
F
Brütsch
H P
HP
D004087:Dihydroergotamine / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D011183:Postoperative Complications / Q000139:chemically induced* / Q000517:prevention & control*; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000517:prevention & control; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control
D006495:Heparin, Low-Molecular-Weight; D004087:Dihydroergotamine; D006493:Heparin